$0.08
(Market cap
$14 Mln
Recently Viewed
Clear AllMarket cap
$14 Mln
Revenue (TTM)
$17 Mln
P/E Ratio
--
P/B Ratio
5.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-3.4 %
ROCE
-- %
Industry P/E
45.48
EV/EBITDA
-0.2
Debt to Equity
3.3
Book Value
$0.3
EPS
$-2
Face value
--
Shares outstanding
11,821,413
CFO
$-63.60 Mln
EBITDA
$-88.54 Mln
Net Profit
$-84.79 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vivos Therapeutics (VVOS)
| -36.1 | 4.7 | -33.4 | -44.3 | -45.5 | -64.1 | -- |
|
BSE Sensex*
| -9.2 | 1.1 | -8.4 | 2.2 | 8.4 | 9.9 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Vivos Therapeutics (VVOS)
| -52.7 | -65.2 | 23.8 | -82.1 | -61.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vivos Therapeutics (VVOS)
|
1.3 | 14.3 | 17.3 | -17.1 | -98.1 | -493 | -- | 5.6 |
| 8.2 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 277.0 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 40.0 | 5,721.9 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.3 | |
| 121.2 | 6,760.4 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.3 | |
| 82.7 | 5,246.6 | 1,541.6 | 233.6 | 21.6 | 21.4 | 23.6 | 4.8 | |
| 178.5 | 9,337.3 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 332.1 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 | |
| 130.8 | 6,773.6 | 738.3 | 48.9 | 11.4 | 2.4 | 139.7 | 3.2 | |
| 34.4 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a... non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado. Address: 7921 Southpark Plaza, Littleton, CO, United States, 80120 Read more
Co-Founder, Chairman of the Board & CEO
Mr. R. Kirk Huntsman
Co-Founder, Chairman of the Board & CEO
Mr. R. Kirk Huntsman
Headquarters
Littleton, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Vivos Therapeutics Inc (VVOS) is $1.30 (NASDAQ) as of 14-Apr-2026 15:33 EDT. Vivos Therapeutics Inc (VVOS) has given a return of -45.46% in the last 3 years.
Since, TTM earnings of Vivos Therapeutics Inc (VVOS) is negative, P/E ratio is not available.
The P/B ratio of Vivos Therapeutics Inc (VVOS) is 5.65 times as on 13-Apr-2026, a 75 premium to its peers’ median range of 3.22 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.93
|
2.70
|
|
2023
|
-0.92
|
30.27
|
|
2022
|
-0.02
|
0.08
|
|
2021
|
-0.11
|
0.09
|
|
2020
|
-0.49
|
0.35
|
The 52-week high and low of Vivos Therapeutics Inc (VVOS) are Rs 7.95 and Rs 1.09 as of 15-Apr-2026.
Vivos Therapeutics Inc (VVOS) has a market capitalisation of $ 14 Mln as on 13-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vivos Therapeutics Inc (VVOS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.